Thus, GnRH-a treatment did not increase obesity, as patients with CPP maintained their baseline BMI-SDS during treatment, despite an overall increase in BMI following GnRH-a therapy [26]. This evidence concerns the gene GNRH1 and obesity due to melanocortin 4 receptor deficiency.